Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal

Dwayne Boyers; Corinne Booth; Moira Cruickshank; Mary Kilonzo; David Cooper; Paul Manson; Michael  Braun; Miriam Brazzelli

Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal

Dwayne Boyers^* (Corresponding Author)
, Corinne Booth
, Moira Cruickshank
, Mary Kilonzo
, David Cooper
, Paul Manson
, Michael Braun
, Miriam Brazzelli

^*Corresponding author for this work

Research output: Book/Report › Commissioned Report

Abstract

Documents containing the evidence that was used to develop the recommendations.

Original language	English
Publisher	Aberdeen HTA Group
Commissioning body	National Institute for Health and Care Excellence (NICE)
Publication status	Published - 25 Apr 2024

Bibliographical note

Contribution of authors
Moira Cruickshank reviewed and critiqued the clinical effectiveness evidence presented in the company submission; David Cooper checked and critiqued the statistical analyses presented in the company submission; Dwayne Boyers, Corinne Booth and Mary Kilonzo reviewed and critiqued the cost-effectiveness evidence and the economic model; Paul Manson checked and critiqued the company’s search strategies; Michael Braun provided clinical guidance and comments on the draft report. Dwayne Boyers and Miriam Brazzelli coordinated all aspects of this appraisal and are the guarantors of this report. All authors contributed to the writing of this report and approved its final version.

Funding

Source of funding: This report was commissioned by the NIHR Evidence Synthesis Programme as project number 136274.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://www.nice.org.uk/guidance/ta1079/evidenceLicence: Other

Cite this

@book{38f541f04ed448d88c7fdb32d7c2af3d,

title = "Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal",

abstract = "Documents containing the evidence that was used to develop the recommendations. ",

author = "Dwayne Boyers and Corinne Booth and Moira Cruickshank and Mary Kilonzo and David Cooper and Paul Manson and Michael Braun and Miriam Brazzelli",

note = "Contribution of authors Moira Cruickshank reviewed and critiqued the clinical effectiveness evidence presented in the company submission; David Cooper checked and critiqued the statistical analyses presented in the company submission; Dwayne Boyers, Corinne Booth and Mary Kilonzo reviewed and critiqued the cost-effectiveness evidence and the economic model; Paul Manson checked and critiqued the company{\textquoteright}s search strategies; Michael Braun provided clinical guidance and comments on the draft report. Dwayne Boyers and Miriam Brazzelli coordinated all aspects of this appraisal and are the guarantors of this report. All authors contributed to the writing of this report and approved its final version.",

year = "2024",

month = apr,

day = "25",

language = "English",

publisher = "Aberdeen HTA Group",

}

TY - BOOK

T1 - Fruquintinib for previously treated metastatic colorectal cancer [ID6274]

T2 - NICE Single Technology Appraisal

AU - Boyers, Dwayne

AU - Booth, Corinne

AU - Cruickshank, Moira

AU - Kilonzo, Mary

AU - Cooper, David

AU - Manson, Paul

AU - Braun, Michael

AU - Brazzelli, Miriam

N1 - Contribution of authors Moira Cruickshank reviewed and critiqued the clinical effectiveness evidence presented in the company submission; David Cooper checked and critiqued the statistical analyses presented in the company submission; Dwayne Boyers, Corinne Booth and Mary Kilonzo reviewed and critiqued the cost-effectiveness evidence and the economic model; Paul Manson checked and critiqued the company’s search strategies; Michael Braun provided clinical guidance and comments on the draft report. Dwayne Boyers and Miriam Brazzelli coordinated all aspects of this appraisal and are the guarantors of this report. All authors contributed to the writing of this report and approved its final version.

PY - 2024/4/25

Y1 - 2024/4/25

N2 - Documents containing the evidence that was used to develop the recommendations.

AB - Documents containing the evidence that was used to develop the recommendations.

M3 - Commissioned Report

BT - Fruquintinib for previously treated metastatic colorectal cancer [ID6274]

PB - Aberdeen HTA Group

ER -

Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Fingerprint

Cite this